Pibit.ai

pibit.ai →

+110%

est. 2Y upside i

InsurTechAI & MLSeries A

The fastest path from submission to better decisions.

Rank

#435

Sector

Insurtech, Artificial Intelligence

Est. Liquidity

~6Y

Data Quality

Data: Low

Pibit.ai's 118% YoY ARR growth to $9.8M is a genuinely compelling signal, and the $25.7B AI-in-insurance TAM is real — this is one of the stronger early-stage growth profiles in the insurtech space.

Last updated: May 14, 2026

Bull (35%)+300%

Pibit.ai sustains ~80% YoY growth off its $9.8M ARR base, reaching $35-40M ARR by late 2026 and raising a Series B/C at $250-350M post-money valuation. Net of ~20-25% dilution from the next round, early employees see ~3-4x paper appreciation on common stock — though liquidity remains years away.

Base (35%)+75%

Growth moderates to 50-60% YoY as the sales cycle lengthens and competition from Duck Creek and EZLynx intensifies; ARR reaches ~$22-25M by 2027 and the company raises a Series B at ~$120-150M. After dilution, common stockholders see roughly 75% paper appreciation with no near-term exit on the horizon.

Bear (30%)-70%

Enterprise insurance carriers prove slow to adopt unproven AI vendors, growth stalls below 30% YoY, and $7.5M in total funding forces a distressed bridge or down round within 18 months. Liquidation preferences ($7.5M) consume the bulk of any recovery, leaving common stock at roughly 30 cents on the grant-date dollar.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Funding Intensity

19%

$7.5M in total liquidation preferences sits ahead of all common stock; based on an estimated ~$40M post-money valuation, the preference stack consumes roughly 18-19% of current enterprise value — firmly in the high-risk tier — and any exit below ~$15M returns near-zero to employees.

Dilution Risk

high

At Series A with only $7.5M raised, Pibit.ai will almost certainly require 2-3 additional funding rounds (Series B, C, and possibly growth equity) before any liquidity event, implying 40-60% cumulative dilution of current common equity.

Secondary Liquidity

none

No secondary market exists for this Series A-stage company; employees are fully illiquid until a tender offer, M&A event, or IPO — none of which are likely within the 2-year analysis horizon.

Questions to Ask at the Interview

Strategic questions based on Pibit.ai's data — designed to show you've done your homework.

  • 1

    “What is the current post-money valuation and fully-diluted share count — and what was the 409A fair market value at the last independent appraisal, so I can assess my strike price relative to current company value?”

  • 2

    “With $7.5M in total funding and 125 employees, what is your current monthly burn rate and how many months of runway does the Series A provide before you need to raise again?”

  • 3

    “What is your net revenue retention across your current customer base, and how does CURE™ contract value scale as carriers increase submission volume through the platform?”

Community

Valuation Sentiment

Our model estimates +110% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.